Dashenlin Pharm Grp Co Ltd
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.
Market Cap & Net Worth: Dashenlin Pharm Grp Co Ltd (603233)
Dashenlin Pharm Grp Co Ltd (SHG:603233) has a market capitalization of $2.96 Billion (CN¥21.72 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #7270 globally and #1218 in its home market, demonstrating a -3.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dashenlin Pharm Grp Co Ltd's stock price CN¥19.07 by its total outstanding shares 1138848067 (1.14 Billion).
Dashenlin Pharm Grp Co Ltd Market Cap History: 2017 to 2026
Dashenlin Pharm Grp Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $2.73 Billion to $2.96 Billion (5.41% CAGR).
Dashenlin Pharm Grp Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dashenlin Pharm Grp Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.09x
Dashenlin Pharm Grp Co Ltd's market cap is 0.09 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.56x
Dashenlin Pharm Grp Co Ltd's market cap is 2.56 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $2.73 Billion | $7.42 Billion | $474.96 Million | 0.37x | 5.74x |
| 2018 | $2.12 Billion | $8.86 Billion | $531.63 Million | 0.24x | 4.00x |
| 2019 | $3.67 Billion | $11.14 Billion | $702.66 Million | 0.33x | 5.22x |
| 2020 | $6.66 Billion | $14.58 Billion | $1.06 Billion | 0.46x | 6.27x |
| 2021 | $4.36 Billion | $16.76 Billion | $791.23 Million | 0.26x | 5.51x |
| 2022 | $5.01 Billion | $21.25 Billion | $1.04 Billion | 0.24x | 4.83x |
| 2023 | $3.86 Billion | $24.53 Billion | $1.17 Billion | 0.16x | 3.31x |
| 2024 | $2.34 Billion | $26.50 Billion | $914.75 Million | 0.09x | 2.56x |
Competitor Companies of 603233 by Market Capitalization
Companies near Dashenlin Pharm Grp Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Dashenlin Pharm Grp Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Dashenlin Pharm Grp Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Dashenlin Pharm Grp Co Ltd's market cap moved from $2.73 Billion to $ 2.96 Billion, with a yearly change of 5.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.96 Billion | +8.23% |
| 2025 | CN¥2.73 Billion | +17.00% |
| 2024 | CN¥2.34 Billion | -39.52% |
| 2023 | CN¥3.86 Billion | -22.79% |
| 2022 | CN¥5.01 Billion | +14.90% |
| 2021 | CN¥4.36 Billion | -34.58% |
| 2020 | CN¥6.66 Billion | +81.41% |
| 2019 | CN¥3.67 Billion | +72.75% |
| 2018 | CN¥2.12 Billion | -22.10% |
| 2017 | CN¥2.73 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Dashenlin Pharm Grp Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.96 Billion USD |
| MoneyControl | $2.96 Billion USD |
| MarketWatch | $2.96 Billion USD |
| marketcap.company | $2.96 Billion USD |
| Reuters | $2.96 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.